The Arizona Cancer Center in Tucson has received a 5-year, $500,000 unrestricted cancer research grant from Bristol-Myers Squibb, making the center one of a select group of institutions worldwide to receive this no-strings-attached funding. Sydney E. Salmon, md, Regents Professor of Medicine and director of the cancer center, will serve as the administrator of the grant.
This prestigious award will enable us to pursue what we consider to be the most promising leads in basic and clinical cancer research, Salmon stated. Peer-reviewed awards, such as this one, provide tangible evidence that our center is in fact a leader in cancer research.
Grant to Be Used for Research on New Drug Development
Bristol-Myers Squibb created the unrestricted biomedical research grant to allow scientists the freedom to explore uncharted areas of research. The center will use the funds for new drug development research efforts related to cancer prevention and treatment. Special focus will be placed on drug design based on the ability of the drugs to inhibit tumor cell growth by attacking the pathways required for growth to occur.
The cancer grants program is one of six biomedical research grants programs funded by Bristol-Myers Squibb. Since the programs launch in 1977, more than $22 million in unrestricted funding has been committed to cancer research.
As grant administrator, Salmon will serve on the Cancer Selection Committee, which is comprised of the principal investigators of all current unrestricted cancer research grants. This independent peer committee selects the winner of the annual $50,000 Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research.